Eli Lilly loses 18 trillion yen in total market capitalization - development progress of competitor companies for obesity drugs
2024/7/26 9:37 JST (some excerpts)
Shares fell 14% in 8 business days, slowest performance since 2020
Advances in clinical trials between Viking and Roche induce Lilly stock sell-off
The US pharmaceutical company Eli Lilly's position as a symbol of the obesity drug boom is being threatened. Since at least 2 competitors announced promising development status for obesity drugs, Lily's total stock market value decreased by more than 120 billion dollars (about 18 trillion yen).
Lily's stock price fell 4.5% on the 25th, hitting a low since May. It has fallen 14% over the past 8 business days, the lowest performance since 2020 for the same period.
Shares fell 14% in 8 business days, slowest performance since 2020
Advances in clinical trials between Viking and Roche induce Lilly stock sell-off
The US pharmaceutical company Eli Lilly's position as a symbol of the obesity drug boom is being threatened. Since at least 2 competitors announced promising development status for obesity drugs, Lily's total stock market value decreased by more than 120 billion dollars (about 18 trillion yen).
Lily's stock price fell 4.5% on the 25th, hitting a low since May. It has fallen 14% over the past 8 business days, the lowest performance since 2020 for the same period.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
